Dvanced Bc News Today

The European Medicines Agency has recommended Fruzaqla, Truqap, and Eribulin Baxter for use in the treatment of specific colorectal and breast cancers.

Simulation models indicate that breast cancer screening and treatment were associated with a 58% reduction in mortality, based on data collected between 1975 and 2019.

Adapting chemo-free maintenance strategies in TNBC could offer effective disease control while improving patients' quality of life.

Patients with breast cancer might be eligible to enroll in one of these clinical trials.

Here's a roundup of the most recent data from five phase 3 trials presented at SABCS 2023.

Older patients with advanced HER2+ breast cancer do not experience a survival benefit with trastuzumab emtansine vs standard-of-care combination therapy, although toxicity is improved, a trial shows.

If approved, the ADC would join sacituzumab govitecan (Trodelvy, Gilead) as agents that target trophoblast cell-surface antigen-2 (Trop-2), which is universally expressed in breast cancer.

In previously treated patients with locally advanced unresectable or metastatic HER2-positive breast cancer, tucatinib and trastuzumab emtansine improved progression-free survival vs T-DM1 alone.